Results 271 to 280 of about 110,227 (357)

Type 2 diabetes subphenotypes are associated with differential outcomes after metabolic and bariatric surgery: An international multicentre retrospective cohort study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3681-3691, May 2026.
Abstract Aims Type 2 diabetes (T2D) is characterized by its clinical heterogeneity. Newly described T2D subphenotypes, each with distinct metabolic and co‐morbidity risk profiles, may enable a more personalized care. This study examined whether these subphenotypes can predict outcomes in patients undergoing metabolic and bariatric surgery (MBS ...
Adisa Poljo   +18 more
wiley   +1 more source

Hormone PYY does not Explain the Variability in Weight Loss After Roux-en-Y Gastric Bypass: Evidence From a Meta-Analysis. [PDF]

open access: yesObes Surg
Macanhã Scremin G   +6 more
europepmc   +1 more source

Impact of early and tight HbA1c control on the risk of long‐term complications and cardiovascular death in patients with type 2 diabetes from the Swedish National Diabetes Register

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3997-4009, May 2026.
Abstract Aims To assess the relationship between haemoglobin A1c (HbA1c) levels and incidence of long‐term complications in patients with type 2 diabetes (T2D). Materials and Methods This long‐term, retrospective study acquired patient data from the Swedish National Diabetes Registry and linked national registers between 1 January 1998 and 31 December ...
Julie Mount   +9 more
wiley   +1 more source

Acarbose or Canagliflozin vs. Placebo to Ameliorate Post‐Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4205-4215, May 2026.
ABSTRACT Aims Treatment options for post‐bariatric hypoglycaemia (PBH) are empirical. We aimed to investigate the efficacy and safety of acarbose and canagliflozin for the treatment of PBH. Materials and Methods We performed a randomised, double‐blinded, cross‐over, placebo‐controlled clinical trial where placebo, acarbose 50 mg thrice daily, and ...
Carolina B. Lobato   +9 more
wiley   +1 more source

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction‐Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta‐Analysis of Randomised Clinical Trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4253-4260, May 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity‐management modalities exert weight‐independent hepatic effects remains uncertain.
Matteo Monami   +11 more
wiley   +1 more source

FNDC4 and FNDC5 Attenuate SARS‐CoV‐2 S1‐Induced Inflammatory Responses in Human Adipose Tissue

open access: yesEuropean Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
In obesity, reduced FNDC4 and FNDC5 amplify SARS‐CoV‐2 S1–driven inflammation in visceral adipose tissue. These adipo‐myokines limit adipocyte–macrophage inflammatory signalling, suggesting a protective role against viral‐induced adipose tissue dysfunction.
Gabriela Neira   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy